Although tPA is recognized as an effective clot-dissolving therapy for ischemia, its clinical application is restricted by a narrow therapeutic window of approximately three hours after stroke symptom onset (Ringleb et al. 2002; Lees et al. 2010). This evidence concerns the gene PLAT and Stroke.